268600 — Cellivery Therapeutics Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Annual income statement for Cellivery Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2,074 | 762 | 3,872 | 23,158 | 18,863 |
| Cost of Revenue | |||||
| Gross Profit | -1,902 | -723 | 70.6 | -269 | 190 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 16,658 | 18,373 | 31,921 | 93,411 | 47,212 |
| Operating Profit | -14,584 | -17,612 | -28,048 | -70,253 | -28,349 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -19,577 | -17,937 | -29,682 | -75,018 | -34,007 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -19,650 | -17,248 | -28,069 | -75,159 | -34,036 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -19,650 | -17,248 | -28,069 | -75,159 | -32,571 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -19,650 | -17,248 | -28,069 | -75,159 | -32,571 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -632 | -535 | -834 | -2,900 | -694 |
| Dividends per Share |